Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
CHRU de Tours, Laboratoire d'Immunologie, Tours, France; Université François-Rabelais de Tours, Tours, France.
Benjamin
B
Chaigne
CHRU de Tours, Laboratoire d'Immunologie, Tours, France; Université François-Rabelais de Tours, Tours, France; UMR 7292, Tours, France; CNRS, UMR 7292, Tours, France. Electronic address: watier@med.univ-tours.fr.
Hervé
H
Watier
D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000235:genetics / Q000627:therapeutic use; D000936:Antigen-Antibody Complex / Q000096:biosynthesis*; D054796:Drug Dosage Calculations; D000939:Epitopes / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007116:Immunization, Passive; D015166:Monitoring, Immunologic / Q000379:methods*; D017354:Point Mutation; D015202:Protein Engineering
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D000939:Epitopes